FDA, again [R for BE/BA]

posted by Helmut Homepage – Vienna, Austria, 2020-01-09 16:04 2a02:8388:6bc2:ce80:40c2:df4:cd8a:8939 – Posting: # 21070
Views: 984

[image] Dear all,

we know that the FDA uses R internally, e.g., in all simulations which lead to its reference-scaling method for NTIDs.

THX to ElMaestro discovering another example. Though I attended the 4th GBHI workshop last month in Bethesda, it is hidden in the backup slides.* Quote:

Q1. What is a sample size to achieve 80% power to pass bioequivalence, assuming CV as 100%, T/R true ratio as 5%?
Q2. With a fixed sample size (n=1,000), what are maximum differences in FEV1 metrics which pass BE with 80% power?

To address questions 1–2;


Of note, Robert Lionberger (Director Office of Research and Standards, Office of Generic Drugs) told me that he visits the forum regularly. :thumb up:



Cheers,
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
20,465 posts in 4,298 threads, 1,414 registered users;
online 6 (0 registered, 6 guests [including 4 identified bots]).
Forum time (Europe/Vienna): 16:41 CEST

Confidence is the result of hours and days and weeks and years
of constant work and dedication.    Roger Staubach

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5